Indication: Thymoglobulin® (anti-thymocyte globulin (rabbit)) is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.
Indication: Thymoglobulin® (anti-thymocyte globulin (rabbit)) is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.

Kidney Transplant Acute Rejection

Both Recipient and Donor Risk Factors Should Be Considered When Evaluating Risk of Acute Rejection1,2

Many Factors Are Associated With an Increased Risk of Acute Rejection1-3
Both recipient and donor risk factors should be considered when evaluating risk for acute rejection of a kidney transplant chart
The presence of only 1 risk factor may lead to acute rejection2

Protection Against Acute Rejection Is a Critical Step to Preserve Kidney Function4

Acute rejection affecting renal function can have a major impact on graft survival, causing nearly 20% of all graft failures in the first year of transplant4,5
Nearly 62% of all graft failures in the 1st year after kidney transplant is due to acute rejection
*Return to normal was defined as SCr <130 µmol /L .
What impact does acute rejection have at your center?
Learn About Thymoglobulin
Learn More

Important Safety Information

WARNING: IMMUNOSUPPRESSION. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.

Important Safety Information

WARNING: IMMUNOSUPPRESSION. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.

Click here for full Prescribing Information including Boxed WARNING.

Abbreviations: CIT, cold ischemia time; cPRA, calculated panel reactive antibodies; DGF, delayed graft function; DSA, donor-specific antibodies; HLA, human leukocyte antigen; KDPI, Kidney Donor Profile Index; LURD, living unrelated donor; SCr, serum creatinine.

References:
  1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):S1-S157.
  2. Lebranchu Y, Baan C, Biancone L, et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int. 2014;27(2):129-138.
  3. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2018 Annual Report: Kidney. Am J Transplant. 2020;20(suppl s1):20-130.
  4. Opelz G, Döhler B; Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation. 2008;85(5):661-666.
  5. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):527-535.
  6. Ndemera H, Bhengu B. Factors contributing to kidney allograft loss and associated consequences among post kidney transplantation patients. Health Sci J. 2017;11(3):504.
  7. Ouellette A, Achille MA, Vachon M. Psychological impact of kidney graft failure and implications for the psychological evaluation of re-transplant candidates. Dial Transplant. June 2006:1-5.
  8. Koo EH, Jang HR, Lee JE, et al. The impact of early and late acute rejection on graft survival in renal transplantation. Kidney Res Clin Pract. 2015;34(3):160-164.
  9. Schnitzler MA, Johnston K, Axelrod D, et al. Associations of renal function at 1-year after kidney transplantation with subsequent return to dialysis, mortality, and healthcare costs. Transplantation. 2011;91(12):1347-1356.
  10. Gheorghian A, Schnitzler MA, Axelrod DA, et al. The implications of acute rejection and reduced allograft function on health care expenditures in contemporary US kidney transplantation. Transplantation. 2012;94(3):241-249.
  11. Schnitzler MA, Woodward RS, Lowell JA, et al. Economics of the antithymocyte globulin Thymoglobulin® and Atgam® in the treatment of acute renal transplant rejection. Pharmacoeconomics. 2000;17(3):287-293.
  12. Ahmad I. Biopsy of the transplanted kidney. Semin Intervent Radiol. 2004;21(4):275-281.
  13. Snyder JJ, Salkowski N, Wey A, et al. Effects of high-risk kidneys on Scientific Registry of Transplant Recipients program quality reports. Am J Transplant. 2016;16(9):2646-2653.